ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Subscribe To Our Newsletter & Stay Updated